2006
DOI: 10.1159/000093226
|View full text |Cite
|
Sign up to set email alerts
|

Low-Density Lipoprotein-Lowering Medication and Platelet Function

Abstract: Elevated low-density lipoprotein (LDL) cholesterol (LDL-C) levels represent one of the most important risk factors for atherosclerosis and therefore cardiovascular morbidity and mortality. LDL-C operates at different levels and through various classic and non-classic mechanisms. In particular, increased or modified LDL enhances platelet function and increases sensitivity of platelets to several naturally occurring agonists. Agents that lower LDL-C in hypercholesterolemic patients have been shown to interfere w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
13
1
4

Year Published

2008
2008
2023
2023

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 26 publications
(18 citation statements)
references
References 146 publications
(80 reference statements)
0
13
1
4
Order By: Relevance
“…Moreover, statins modulate the functions of cells that are involved in innate and adaptive responses and the production of cytokines and cellular adhesion molecules such as intercellular adhesion molecule 1, interleukin‐6, tumor necrosis factor α, interleukin‐1, and selectin levels (16). Finally, the statins also exhibit an antithrombotic effect by inhibiting platelet activation (17).…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, statins modulate the functions of cells that are involved in innate and adaptive responses and the production of cytokines and cellular adhesion molecules such as intercellular adhesion molecule 1, interleukin‐6, tumor necrosis factor α, interleukin‐1, and selectin levels (16). Finally, the statins also exhibit an antithrombotic effect by inhibiting platelet activation (17).…”
Section: Discussionmentioning
confidence: 99%
“…Nonetheless, it has been demonstrated that HCh enhances thromboembolism in arterioles (but not venules) and this response can be completely reversed by L‐arginine supplementation. The latter findings suggest that HCh (possibly through oxLDL) promotes thrombosis by reducing NO bioavailability, which can be overcome by stimulating endogenous NO production with excess L‐arginine [25,46,47,87].…”
Section: Platelet Recruitment and Thrombosismentioning
confidence: 99%
“…Patients with elevated low-density lipoprotein cholesterol levels have enhanced platelet reactivity and elevated 11-dehydro thromboxane B 2 concentrations in the urine. 24 Statins inhibit platelet hyperreactivity and reduce urinary 11-dehydro thromboxane B 2 concentrations in patients with type IIa hypercholesterolemia, 24,25 and they improve endothelial function in patients with coronary artery disease. 26,27 Reduced tissue factor expression and release from dysfunctional endothelium during statin therapy may reduce generation of thrombin, a powerful platelet agonist, and thereby reduce platelet activation and aggregation.…”
Section: Eikelboom Et Al Asa-insensitive Thromboxane Biosynthesismentioning
confidence: 99%